- Home
- DEA vs VOR Comparison
DEA vs VOR Comparison
Compare DEA & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DEA | VOR |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DEA | VOR |
|---|---|---|
| Price | $21.81 | $18.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $25.36 | ★ $39.00 |
| AVG Volume (30 Days) | 509.2K | ★ 1.2M |
| Earning Date | 10-26-2026 | 11-12-2026 |
| Dividend Yield | ★ 8.19% | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $336,099,000.00 | N/A |
| Revenue This Year | $7.51 | N/A |
| Revenue Next Year | $2.57 | N/A |
| P/E Ratio | $274.88 | ★ N/A |
| Revenue Growth | ★ 11.27 | N/A |
| 52 Week Low | $20.56 | $6.50 |
| 52 Week High | $25.96 | $30.40 |
Technical Indicators
Market Signals| Indicator | DEA | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 27.90 | 40.25 |
| Support Level | $21.65 | $17.35 |
| Resistance Level | $23.74 | $18.44 |
| Average True Range (ATR) | 0.48 | 1.18 |
| MACD | -0.08 | 0.10 |
| Stochastic Oscillator | 4.79 | 29.33 |
Price Performance
Historical ComparisonAbout DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. The company is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. It generates all its revenue by leasing its properties to such agencies. The company operates in single segment for the purposes of assessing performance and making operating decisions.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.